Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.
Jeyaraju DV, Alapa M, Polonskaia A, Risueño A, Subramanyam P, Anand A, Ghosh K, Kyriakopoulos C, Hemerich D, Hurren R, Wang X, Gronda M, Ahsan A, Chiu H, Thomas G, Lind EF, Menezes DL, Schimmer AD, Hagner PR, Gandhi A, Thakurta AG. Jeyaraju DV, et al. Among authors: thakurta ag. Haematologica. 2024 Apr 1;109(4):1082-1094. doi: 10.3324/haematol.2023.283437. Haematologica. 2024. PMID: 37941406 Free PMC article.
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
Amatangelo M, Flynt E, Stong N, Ray P, Van Oekelen O, Wang M, Ortiz M, Maciag P, Peluso T, Parekh S, van de Donk NWCJ, Lonial S, Thakurta A. Amatangelo M, et al. Among authors: thakurta a. Cell Rep Med. 2024 May 15:101571. doi: 10.1016/j.xcrm.2024.101571. Online ahead of print. Cell Rep Med. 2024. PMID: 38776914 Free article.
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
Van Oekelen O, Amatangelo M, Guo M, Upadhyaya B, Cribbs AP, Kelly G, Patel M, Kim-Schulze S, Flynt E, Lagana A, Gooding S, Merad M, Jagganath S, Pierceall WE, Oppermann U, Thakurta A, Parekh S. Van Oekelen O, et al. Among authors: thakurta a. Cell Rep Med. 2024 May 17:101584. doi: 10.1016/j.xcrm.2024.101584. Online ahead of print. Cell Rep Med. 2024. PMID: 38776911 Free article.
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
Prabhala R, Pierceall WE, Samur M, Potluri LB, Hong K, Peluso T, Talluri S, Wang A, Katiki A, Vangala SD, Buonopane M, Bade V, Seah H, Krogman A, Derebail S, Fulciniti M, Lazo SB, Richardson P, Anderson K, Corre J, Avet-Loiseau H, Thakurta A, Munshi N. Prabhala R, et al. Among authors: thakurta a. Front Oncol. 2023 Dec 4;13:1271807. doi: 10.3389/fonc.2023.1271807. eCollection 2023. Front Oncol. 2023. PMID: 38111533 Free PMC article.
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.
Neri P, Barwick BG, Jung D, Patton JC, Maity R, Tagoug I, Stein CK, Tilmont R, Leblay N, Ahn S, Lee H, Welsh SJ, Riggs DL, Stong N, Flynt E, Thakurta A, Keats JJ, Lonial S, Bergsagel PL, Boise LH, Bahlis NJ. Neri P, et al. Among authors: thakurta a. Blood Cancer Discov. 2024 Jan 8;5(1):56-73. doi: 10.1158/2643-3230.BCD-23-0061. Blood Cancer Discov. 2024. PMID: 37934799 Free PMC article.
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Mitchell JL, Khan D, Rana RH, Kriek N, Unsworth AJ, Sage T, Bye AP, Laffan M, Shapiro S, Thakurta A, Grech H, Ramasamy K, Gibbins JM. Mitchell JL, et al. Among authors: thakurta a. Platelets. 2023 Dec;34(1):2264940. doi: 10.1080/09537104.2023.2264940. Epub 2023 Oct 11. Platelets. 2023. PMID: 37822056 Free article.
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U. Kurata K, et al. Among authors: thakurta a. Blood Cancer J. 2023 Feb 7;13(1):24. doi: 10.1038/s41408-023-00793-y. Blood Cancer J. 2023. PMID: 36746923 Free PMC article. No abstract available.
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U. Kurata K, et al. Among authors: thakurta a. Blood Cancer J. 2023 Jan 12;13(1):12. doi: 10.1038/s41408-023-00787-w. Blood Cancer J. 2023. PMID: 36631435 Free PMC article.
61 results